Cancer Letters
Volume 238, Issue 2 , Pages 188-196 , 18 July 2006

Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer

  • Maja Prutki

      Affiliations

    • University of Zagreb, Medical School, Zagreb, Croatia
    • ,
  • Marija Poljak-Blazi

      Affiliations

    • Laboratory for Oxidative Stress, Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, HR-10000 Zagreb, Croatia
    • ,
  • Marko Jakopovic

      Affiliations

    • University of Zagreb, Medical School, Zagreb, Croatia
    • ,
  • Davor Tomas

      Affiliations

    • Clinical Hospital ‘Sestre Milosrdnice’, Zagreb, Croatia
    • ,
  • Igor Stipancic

      Affiliations

    • Dubrava University Hospital, Zagreb, Croatia
    • ,
  • Neven Zarkovic

      Affiliations

    • Laboratory for Oxidative Stress, Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, HR-10000 Zagreb, Croatia
    • Corresponding Author InformationCorresponding author. Tel.: +385 1 4560 937; fax: +385 1 4561 010.

Received 27 April 2005 ,Revised 1 July 2005 ,Accepted 4 July 2005.

References 

  1. Houlston RS. What we could do now: molecular pathology of colorectal cancer. Mol. Pathol. 2001;54:206–214
  2. Gackowski D, Kruszewski M, Banaskziewicz Z, Jawien A, Olinski R. Lymphocyte labile iron pool, plasma iron, transferrin saturation and ferritin levels in colon cancer patients. Acta Biochim. Pol. 2002;49:269–272
  3. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta. 1997;1331:1–40
  4. White S, Taetle R, Seligman PA, Rutherford M, Trowbridge IS. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res. 1990;506:295–301
  5. Chitambar CR, Matthaeus WG, Antholine WE. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood. 1988;72:1930–1936
  6. Blatt J, Taylor SR, Kontoghiorghes GJ. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res. 1989;49:2925–2927
  7. Faulk WP, His BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet. 1980;2:390–392
  8. Habelshaw JA, Lister TA, Stansfeld AG. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgin lymphoma. Lancet. 1983;1:498–500
  9. Wrba F, Ritzinger E, Reiner A, Holzner JH. Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. Virchows Arch. 1986;410:69–73
  10. Octave JN, Schneider YJ, Hoffman P, Trouet A, Crichton RR. Transferrin protein and iron uptake by cultured rat fibroblasts. FEBS Lett. 1979;108:127–130
  11. Larric JW, Cresswell P. Transferrin receptors on human B and T lymphoblastoid cell lines. Biochim. Biophys. Acta. 1979;583:483–490
  12. Larson SM, Rasey RS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J. Natl. Cancer Inst. 1980;64:41–53
  13. Delia D, Greaves MF, Newan RA. Modulation of T leukaemic cell phenotype with phorbol ester. Int. J. Cancer. 1982;29:23–31
  14. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin. Hematol. 1998;35:35–54
  15. Kishida T, Shinozawa I, Tanaka S, Hoshino T, Tatsuguchi A, Feng L. Significance of serum iron and ferritin in patients with colorectal cancer. J. Gastroenterol. 1997;32:233–237
  16. Mainous AG, Gill JM, Everet CJ. Transferrin saturation, dietary iron intake, and risk of cancer. Ann. Fam. Med. 2005;3:131–137
  17. Birgegard G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, et al. Cancer-related anemia: Pathogenesis, prevalence and treatment. Oncology. 2005;68:3–11
  18. Labropoulou EP, Datsis A, Kekelos S, Rogdakis A, Katsiki E, Labropoulou CM, et al. The presence and significance of iron in neoplasia of the colorectum. Tech. Coloproctol. 2004;8:211–213
  19. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. New York: Wiley-Liss; 2002;pp. 60–64
  20. Whitney JF, Clarc JM, Griffin TW, Gautman S, Leslie KO. Transferrin receptor expression in nonsmall cell lung cancer, Histopathologic and clinical correlates. Cancer. 1995;76:20–25
  21. Yang HB, Hsu PI, Lee JC, Chan SH, Lin XZ, Chow NH. Adenoma-carcinoma sequence: a reappraisal with immunohistochemical expression of ferritin. J. Surg. Oncol. 1995;60:35–40
  22. Hyman GA, Harvey JE. The pathogensis of anaemia in patients with carcinoma. Am. J. Med. 1955;19:350–356
  23. Hsu PI, Chow NH, Lin XZ. Prognostic significance of ferritin expression in colorectal adenocarcinoma. Anticancer Res. 1995;5:1087–1093
  24. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Clarendon Press; 1989;pp. 466–508
  25. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors, the gastrointestinal tumor study group experience. Cancer. 1986;57:1866–1870
  26. Griffin MP, Bergstrahl EJ, Coffey RJ. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer. 1987;60:2318–2324
  27. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur. J. Cancer. 2004;40:1418–1422
  28. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia, HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J. Biol. Chem. 1999;274:24142–24146
  29. Biasi F, Tessitore L, Zanetti D, Cutrin JC, Zingaro B, Chiarpotto E, et al. Associated changes of lipid peroxidation and TGFb1 levels in human cancer during tumor progression. Gut. 2002;50:361–367
  30. Yamaguchi K, Shimada S, Tashima S. A potentially novel peptidase, resembling but distinct from neutrophil elastase, produced by carcinoma cells. Oncol. Rep. 2000;7:1017–1021
  31. Sun Z, Yang P. Role of imbalance between neutrophil elastase and α1-antitrypsin in cancer development and progression. Lancet Oncol. 2004;5:182–190
  32. Graziadei S, Gaggl R, Kaserbacher . The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood. 1994;83:260–268
  33. Yang P, Cunningham JM, Halling KC, Lesnick TG, Burgart LJ, Wiegert EM, et al. Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol. Genet. Metab. 2000;71:639–645
  34. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA. 1982;79:1175–1179

PII: S0304-3835(05)00656-7

doi: 10.1016/j.canlet.2005.07.001

Cancer Letters
Volume 238, Issue 2 , Pages 188-196 , 18 July 2006

Article Tools

* Image Usage & Resolution